All In Biotech

Drug Trial Radar · NCT06137118

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

255

Planned (sponsor's estimate)

Start

Dec 29, 2023

Primary completion

Jan 6, 2028

Study completion Aug 10, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in participants with R/R B ALL. The study will consist of 4 parts. Part A: monotherapy dose escalation in 3L+ B-ALL. Part B: dose optimization in 3L+ B-ALL. Part C: Dose expansion in 3L+ B-ALL. Part D: Dose optimization and efficacy expansion in R/R B-ALL (2L+)

Conditions

  • B-cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

  • SurovatamigDrug

    Investigational Product administered via intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Frequency of DLTsTime frame: Up to 28 days
  2. Parts A & B: Safety Evaluation of AZD0486Time frame: From signing of informed consent through data cutoff, up to 57 months
  3. Parts B & C: Rate of CR within 3 cyclesTime frame: Up to three cycles of 28 days each
  4. Part D: CR/CRh within 3 cyclesTime frame: Up to three cycles of 28 days each

Locations

83 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama · Withdrawn

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Palo Alto, California · Recruiting

  • Research Site

    Tampa, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Richmond, Virginia · Recruiting

  • Research Site

    Seattle, Washington · Withdrawn

  • Research Site

    Milwaukee, Wisconsin · Recruiting

  • Research Site

    Melbourne, Australia · Withdrawn

  • Research Site

    Porto Alegre, Brazil · Suspended

  • Research Site

    São Paulo, Brazil · Suspended

  • Research Site

    São Paulo, Brazil · Suspended

  • Research Site

    Toronto, Ontario, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Withdrawn

  • Research Site

    Montreal, Quebec, Canada · Withdrawn

  • Research Site

    Changsha, China · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Hangzhou, China · Recruiting

  • Research Site

    Nanjing, China · Recruiting

  • Research Site

    Nanjing, China · Recruiting

  • Research Site

    Suzhou, China · Recruiting

  • Research Site

    Tianjin, China · Recruiting

  • Research Site

    Zhengzhou, China · Recruiting

  • Research Site

    Caen, France · Suspended

  • Research Site

    Marseille, France · Recruiting

  • Research Site

    Nantes, France · Suspended

  • Research Site

    Paris, France · Recruiting

  • Research Site

    Pierre-Bénite, France · Suspended

  • Research Site

    Toulouse, France · Suspended

  • Research Site

    Berlin, Germany · Not yet recruiting

  • Research Site

    Cologne, Germany · Recruiting

  • Research Site

    Düsseldorf, Germany · Recruiting

  • Research Site

    Essen, Germany · Withdrawn

  • Research Site

    Frankfurt, Germany · Recruiting

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.